Loading...
•
Dec 31, 2019
Insulet Q4 2019 Earnings Report
Insulet's Q4 2019 revenue increased by 27% year-over-year, exceeding guidance. The company is on track to meet its 2021 financial targets.
Key Takeaways
Insulet Corporation reported a strong Q4 2019 with revenue reaching $209.4 million, a 27% increase year-over-year, exceeding the company's guidance. The company's Omnipod products saw significant growth, particularly in the US. Insulet is progressing towards its 2021 financial goals.
Q4 2019 revenue reached $209.4 million, a 27% increase year-over-year.
Total Omnipod revenue increased by 30% to $192.5 million.
U.S. Omnipod revenue increased by 36% to $126.7 million.
Net income was $5.0 million, or $0.08 per diluted share.
Revenue by Segment
Forward Guidance
For the quarter ending March 31, 2020, the Company expects revenue growth of 17% to 20%, including a negative foreign currency impact of approximately 1%. Revenue growth ranges by product line are: Total Omnipod of 23% to 26%, including a negative foreign currency impact of approximately 1% U.S. Omnipod of 27% to 29% International Omnipod of 17% to 20%, including a negative foreign currency impact of approximately 3% Drug Delivery decline of 28% to 34%
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...